[PDF][PDF] Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
Mucosal COVID-19 vaccines are needed to block SARS-CoV-2 infection at the mucosal site.
Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD)
mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those
induced by the intramuscular injection of the same vaccine or Omicron-S subunit vaccine, as
well as high mucosal IgA antibody responses. It elicited broadly neutralizing antibodies
against the original SARS-CoV-2 strain, Delta and Omicron BA1/BA2 variants, completely …
Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD)
mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those
induced by the intramuscular injection of the same vaccine or Omicron-S subunit vaccine, as
well as high mucosal IgA antibody responses. It elicited broadly neutralizing antibodies
against the original SARS-CoV-2 strain, Delta and Omicron BA1/BA2 variants, completely …
Glycosylated Delta-RBD mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
Mucosal COVID-19 vaccines are needed to block SARS-CoV-2 infection at the mucosal site.
Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD)
mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those
induced by intramuscular injection of the same vaccine or Omicron-S subunit vaccine, as
well as high mucosal IgA antibody responses. It elicited broadly neutralizing antibodies
against the original SARS-CoV-2 strain, Delta and Omicron BA1/BA2 variants, completely …
Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD)
mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those
induced by intramuscular injection of the same vaccine or Omicron-S subunit vaccine, as
well as high mucosal IgA antibody responses. It elicited broadly neutralizing antibodies
against the original SARS-CoV-2 strain, Delta and Omicron BA1/BA2 variants, completely …
